Profile data is unavailable for this security.
About the company
Embla Medical hf, formerly Ossur hf, is an Iceland-based company that operates within the field of medical equipment and supplies sector. The Company is active in the development and distribution of products in the fields of non-invasive prosthetics, medical braces and supports. The Company's business activities are divided into three business segment: The Prosthetics, its product portfolio includes a range of lower and upper limb prosthetic components; The Bracing & Supports, which offers the Unloader One range of knee braces that relieve pain from knee osteoarthritis, as well as the Unloader Hip which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip; and The Patient Care, which operates a network of Patient Care clinics around the world, with each one catering to individual patients and their needs.
- Revenue in DKK (TTM)5.87bn
- Net income in DKK527.05m
- Incorporated1971
- Employees4.19k
- LocationEmbla Medical hfGrjothals 5REYKJAVIK 110IcelandISL
- Phone+354 5151300
- Fax+354 5151366
- Websitehttps://www.emblamedical.com/
More ▼
Mergers & acquisitions
| Acquired company | EMBLA:CPH since announced | Transaction value |
|---|---|---|
| Streifeneder Ortho.Production GmbH | -7.08% | 14.51m |
Data delayed at least 15 minutes, as of Mar 02 2026 15:54 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medistim ASA | 444.58m | 94.70m | 2.78bn | 154.00 | 29.27 | 9.95 | 24.74 | 6.25 | 7.79 | 7.79 | 36.56 | 22.91 | 1.25 | 0.7679 | 9.67 | 4,341,637.00 | 26.72 | 21.98 | 33.09 | 27.19 | 81.21 | 78.66 | 21.30 | 20.32 | 2.03 | -- | 0.0484 | 85.04 | 6.88 | 9.12 | 0.0087 | 8.11 | 12.53 | 16.89 |
| Revenio Group Oyj | 819.69m | 130.02m | 3.71bn | 247.00 | 28.44 | 4.31 | 22.76 | 4.52 | 0.654 | 0.654 | 4.12 | 4.31 | 0.7515 | 3.05 | 7.26 | 444,129.60 | 11.92 | 14.00 | 14.23 | 17.40 | 70.92 | 70.95 | 15.86 | 19.38 | 1.63 | 9.66 | 0.0969 | -- | 5.97 | 12.43 | -5.93 | 5.42 | 22.19 | -- |
| RaySearch Laboratories AB (publ) | 941.60m | 159.54m | 4.13bn | 458.00 | 28.82 | 6.67 | 11.38 | 4.39 | 6.65 | 6.65 | 39.25 | 28.74 | 0.6584 | 6.25 | 2.93 | 2,935,074.00 | 11.16 | 5.26 | 16.21 | 7.77 | 92.42 | 91.01 | 16.94 | 9.70 | 1.66 | 64.92 | 0.2861 | 52.38 | 12.77 | 15.58 | 11.93 | -- | 0.2213 | -- |
| Xvivo Perfusion AB | 568.89m | 17.63m | 4.14bn | 198.00 | 235.33 | 2.79 | 61.93 | 7.27 | 0.7968 | 0.7968 | 25.76 | 67.10 | 0.34 | 0.8939 | 6.13 | 4,101,844.00 | 1.05 | 3.28 | 1.12 | 3.52 | 73.81 | 73.86 | 3.10 | 10.87 | 3.68 | 1.83 | 0.0557 | 0.00 | -1.25 | 35.19 | -85.39 | -- | -- | -- |
| Arjo AB (publ) | 7.71bn | 233.95m | 4.82bn | 6.94k | 22.07 | 0.9884 | 4.82 | 0.6252 | 1.23 | 1.23 | 40.39 | 27.38 | 0.704 | 4.92 | 6.22 | 1,584,702.00 | 2.14 | 3.26 | 2.91 | 4.80 | 42.59 | 43.42 | 3.04 | 4.78 | 0.8494 | 3.99 | 0.4179 | 48.74 | -2.59 | 3.92 | -32.93 | -8.68 | -- | 2.25 |
| ChemoMetec A/S | 493.12m | 177.03m | 7.32bn | 172.00 | 41.33 | 11.21 | 35.80 | 14.84 | 10.17 | 10.17 | 28.33 | 37.50 | 0.6516 | 0.6662 | 5.54 | 2,679,973.00 | 23.39 | 27.48 | 27.93 | 34.02 | 83.83 | 80.53 | 35.90 | 36.41 | 3.06 | 95.21 | 0.0079 | 48.77 | 21.50 | 18.28 | 36.78 | 25.80 | 19.35 | 36.08 |
| Vitrolife AB | 2.41bn | -3.51bn | 9.05bn | 1.15k | -- | 1.64 | -- | 3.76 | -37.01 | -37.01 | 25.39 | 58.29 | 0.2407 | 3.44 | 5.24 | 2,987,837.00 | -35.09 | -9.46 | -36.79 | -9.86 | 58.24 | 57.81 | -145.74 | -49.19 | 2.73 | 11.33 | 0.169 | -- | -4.68 | 22.53 | -1,077.00 | -- | 68.15 | 6.58 |
| AddLife AB | 7.31bn | 392.26m | 12.73bn | 2.30k | 33.56 | 3.45 | 13.26 | 1.74 | 4.60 | 4.60 | 85.69 | 44.66 | 0.8105 | 3.83 | 5.87 | 4,549,891.00 | 4.36 | 3.82 | 6.05 | 5.80 | 38.09 | 37.80 | 5.38 | 4.66 | 0.6257 | 3.68 | 0.4671 | 31.71 | 1.52 | 14.64 | 122.22 | 1.58 | 22.47 | 0.00 |
| Embla Medical hf | 5.87bn | 527.05m | 12.77bn | 4.19k | 24.03 | 2.25 | 13.99 | 2.17 | 1.23 | 1.23 | 13.73 | 13.17 | 0.5681 | 2.27 | 6.96 | 1,401,077.00 | 5.12 | 4.60 | 6.10 | 5.43 | 62.30 | 62.25 | 9.01 | 7.99 | 0.9445 | 7.22 | 0.3768 | 0.00 | 8.63 | 8.09 | 22.05 | 68.07 | 6.12 | -- |
| Elekta AB (publ) | 12.30bn | 204.53m | 14.99bn | 4.48k | 75.92 | 2.63 | 13.56 | 1.22 | 0.7646 | 0.7646 | 45.97 | 22.11 | 0.5781 | 3.35 | 3.09 | 3,872,796.00 | 0.9511 | 3.48 | 1.70 | 6.21 | 38.17 | 38.22 | 1.65 | 6.02 | 0.7918 | 7.51 | 0.4724 | 92.20 | -0.5685 | 4.29 | -81.80 | -26.22 | 15.56 | 5.92 |
| Asker Healthcare Group AB | 11.76bn | 344.63m | 17.27bn | 4.58k | 48.47 | -- | 18.56 | 1.47 | 1.33 | 1.33 | 45.59 | -- | 1.12 | 5.14 | 8.48 | 3,665,284.00 | 3.41 | -- | 4.52 | -- | 40.92 | -- | 3.04 | -- | 0.8497 | 3.20 | 0.4688 | -- | 11.73 | -- | 36.67 | -- | -- | -- |
| Ambu A/S | 6.09bn | 544.00m | 18.68bn | 5.43k | 38.89 | 3.51 | 20.24 | 3.07 | 2.04 | 2.04 | 22.85 | 22.64 | 0.8135 | 1.95 | 7.18 | 1,130,201.00 | 7.27 | 4.06 | 8.49 | 4.82 | 60.07 | 59.33 | 8.94 | 5.48 | 1.67 | 20.74 | 0.0845 | 21.23 | 11.98 | 11.10 | 159.15 | 20.37 | -2.24 | 7.17 |
| Sectra AB | 1.57bn | 452.77m | 24.71bn | 1.32k | 57.72 | 20.86 | 46.36 | 15.77 | 3.36 | 3.36 | 11.62 | 9.29 | 0.6688 | -- | 3.93 | 1,726,353.00 | 19.32 | 15.75 | 35.74 | 29.92 | 54.43 | 60.29 | 28.89 | 22.41 | -- | -- | 0.0505 | 19.27 | 19.85 | 4.47 | 31.51 | 18.87 | 7.19 | -- |
Data as of Mar 02 2026. Currency figures normalised to Embla Medical hf's reporting currency: Danish Krone DKK
23.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Inter Fund Management SAas of 31 Dec 2025 | 42.76m | 10.00% |
| L�feyrissj��ur verslunarmannaas of 31 Dec 2025 | 21.38m | 5.00% |
| SEB Funds ABas of 30 Jan 2026 | 15.14m | 3.54% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 6.64m | 1.55% |
| ODIN Forvaltning ASas of 30 Jan 2026 | 4.98m | 1.16% |
| Artisan Partners LPas of 31 Dec 2025 | 2.38m | 0.56% |
| SEB Investment Management AB (Denmark)as of 30 Jan 2026 | 2.21m | 0.52% |
| DNCA Finance SAas of 30 Jun 2025 | 1.74m | 0.41% |
| Schroder Investment Management (Europe) SA (Finland)as of 31 Dec 2025 | 1.00m | 0.23% |
| Danske Bank A/S (Investment Management)as of 30 Nov 2025 | 861.40k | 0.20% |
More ▼
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
